Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/21/2024 | $70.00 | Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 1/25/2024 | $26.00 | Outperform | Oppenheimer |
| 1/8/2024 | Overweight | Cantor Fitzgerald | |
| 12/18/2023 | $29.00 | Outperform | Raymond James |
| 11/10/2023 | $18.00 → $26.00 | Hold → Buy | Jefferies |
| 8/16/2023 | $27.00 | Buy | Guggenheim |
| 1/4/2023 | $32.00 → $6.00 | Buy → Hold | Jefferies |
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. "We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ
Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 54,050 shares of Class A common stock and restricted stock units (RSUs) for 27,025 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option granted on November 4, 2024 has an exercise price per share equal to $45.17, Vera's closing trading price on November 4
Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics;PIONEER study expands the investigation of atacicept into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of BAFF/APRIL dual inhibition; BRISBANE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, is partnering with the University of Michigan on the Nephrotic Syndrome Study Network (NEP
Wells Fargo initiated coverage of Vera Therapeutics with a rating of Overweight and set a new price target of $70.00
Scotiabank initiated coverage of Vera Therapeutics with a rating of Sector Outperform
Oppenheimer initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $26.00
10-Q - Vera Therapeutics, Inc. (0001831828) (Filer)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
3 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday. Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be acquired by Waste Management Inc. (NYSE:WM) for approximately $7.2 billion, including debt. Stericycle shares climbed 15% to $59.28 on Monday. Here are some other big stocks recording gains in today’s session. GameStop Corp. (NYSE:GME) shares jumped 34.5% to $31.13 after Roaring Kitty on a Reddit post, shared his position on the stock. MarineMax, Inc. (NYSE:HZO) jumped 27% to $36.16. OneWater Marine Inc. is reportedly said to be in advanced discussions to acquire MarineMax. L
The U.S. stock market ended a five-week positive streak as investors feared that slowing economic momentum could impact the earnings outlook for American corporations. The U.S. economy grew at an annualized rate of 1.3% in the first quarter, marking a downward revision from the previous estimate of 1.6%. The Fed's preferred inflation measure remained steady in April, easing some worries about resuming price pressures. Yet, slowing spending and income growth also signaled weakening consumer health, while the Chicago business activity gauge plummeted to its lowest level since May 2020, raising concerns about a potential end-cycle slowdown. The tech sector, as tracked by the Technology
New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la
Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, extending cash runway to Q4 2024 Conference call and webcast to take place on January 30th at 8:00am ET BRISBANE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced results from a prespecified per-protocol (PP)
Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in proteinuria at week 36 Atacicept safety profile in IgAN patients was similar to placebo Vera plans to advance atacicept into a pivotal Phase 3 trial in the first half of 2023 Company to host investor conference call and webcast on January 4, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing